tbuckley/cabot-search huggingface dataset:
LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
Authors: O. Sartor, D.E. Castellano Gauna, K. Herrmann, J.S. de Bono, N.D. Shore, K.N.N. Chi, M. Crosby, J.M. Piulats Rodriguez, A. Flechon, X.X. Wei, H. Mahammedi, G. Roubaud, H. ova, S. Ghebremariam, E. Kpamegan, T.N. Kreisl, N. Delgoshaie, K. Lehnhoff, M.J. Morris, K. Fizazi
Journal: Annals of Oncology (2023)
LBA67 A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
Authors: M-J. Ahn, S. Park, T.M. Kim, J-Y. Han, G-W. Lee, B. Shim, Y-G. Lee, S-W. Kim, I-H. Kim, S. Lee, Y.J. Kim, J.H. Park, S.G. Park, K.H. Lee, E.J. Kang, J.W. Kim, S-H. Shin
Journal: Annals of Oncology (2023)
LBA98 Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial
Authors: C. Proto, S. Manglaviti, G. Galli, M. Imbimbo, M.F. Alvisi, F. Zollo, M.R.A. Perrino, M. Giuliano, E. Pietroluongo, Z. Ballatore, A. Chella, A. Fabbri, R. Vigorito, F.G.M. De Braud, G. Pasello, I. Petrini, R. Berardi, P.A. Zucali, M. Ganzinelli, M.C. Garassino, G. Lo Russo
Journal: Annals of Oncology (2023)
LBA69 Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study
Authors: Y. Hu, F. Zhang, M. Zhao, Z. Zheng, H. Zhang, T. Jiang, Z. Liu, J. Wen, X. Gan, H. Wang, L. Wu, S. Cang, J. Zhao, X. Li, L. Peng, Z. Fan, G. Shen, Q. Zhou, J. Zou
Journal: Annals of Oncology (2023)
LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study
Authors: N. Girard, K. Park, K. Tang, B.C. Cho, L. Paz-Ares, S. Cheng, S. Kitazono, M. Thiagarajan, J.W. Goldman, J.K. Sabari, R.E. Sanborn, A.S. Mansfield, J-Y. Hung, S. Popat, J. Dias, A. Bhattacharya, T. Agrawal, M. Shreeve, R.E. Knoblauch, C. Zhou
Journal: Annals of Oncology (2023)
LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
Authors: K.N.N. Chi, E. Castro, G. Attard, M.R. Smith, S.K. Sandhu, E. Efstathiou, G. Roubaud, E.J.J. Small, A.J.P.D.S. Gomes, D. Rathkopf, M. Saad, H.P. Gurney, W. Jung, G.E. Mason, S. Dibaj, D. Wu, B. Diorio, A. Lopez-Gitlitz, W. Kim, D. Olmos
Journal: Annals of Oncology (2023)
LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
Authors: B.J. Solomon, J.S. Ahn, R. Dziadziuszko, F. Barlesi, M. Nishio, D.H. Lee, J-S. Lee, W-Z. Zhong, H. Horinouchi, W. Mao, M.J. Hochmair, F. de Marinis, M.R. Migliorino, I. Bondarenko, T.O. Lohmann, T. Xu, A. Cardona Gavaldon, W. Bordogna, T. Ruf, Y-L. Wu
Journal: Annals of Oncology (2023)
LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
Authors: T. Cascone, M.M. Awad, J.D. Spicer, J. He, S. Lu, B. Sepesi, F. Tanaka, J.M. Taube, R. Cornelissen, L. Havel, J. Kuzdzal, L.B. Petruzelka, L. Wu, J-L. Pujol, H. Ito, C. Coronado Erdmann, P. Sathyanarayana, S. Meadows-Shropshire, M. Provencio Pulla
Journal: Annals of Oncology (2023)
LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial
Authors: B. Groot Koerkamp, Q.P. Janssen, J.L. van Dam, B.A. Bonsing, H. Bos, K.P. Bosscha, B.C.M. Haberkorn, I.H.J.T. de Hingh, T.M. Karsten, M.B. Van der Kolk, M.S.L. Liem, O.J.L. Loosveld, G.A. Patijn, H.C.M. van Santvoort, None J. de vos-Geelen, B. van der Holt, M.Y.V. Homs, G. van Tienhoven, M.G. Besselink, H.W. Wilmink
Journal: Annals of Oncology (2023)
LBA96 Roxadustat for chemotherapy-induced anemia in patients with non-myeloid malignancies: A randomized, open-label, active-controlled, phase III study
Authors: S. Lu, J. Wu, J. Jiang, Q. Guo, Y. Yu, Y. Liu, H. Zhang, L. Qian, X. Dai, Y. Xie, T. Fu, T. Lee, Y. Lu, R. Ma, M. Eisner
Journal: Annals of Oncology (2023)
LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
Authors: K. Shitara, S.Y. Rha, L.S. Wyrwicz, T. Oshima, N. Karaseva, M. Osipov, H. Yasui, H. Yabusaki, S. Afanasyev, Y-K. Park, S-E. Al-Batran, T. Yoshikawa, P.E. Yanez Weber, M. Di Bartolomeo, S. Lonardi, X. Fang, C-S. Shih, P. Bhagia, Y-J. Bang
Journal: Annals of Oncology (2023)
LBA100 CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes
Authors: H.S. Wasan, J. Wang, E.M. Elaine McCartney, H. Soifer, K. Treuner, Y. Zhang, C. Schnabel, None K. Carty, L. McMahon, T.R.J. Evans, M.C. Nicolson, H. Thygesen, J.R. Roche, K.A. Oien
Journal: Annals of Oncology (2023)
LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Authors: M.C. Garassino, W.S.M.E. Theelen, R. Jotte, J. Laskin, F. de Marinis, C. Aguado, F.B. Badin, I. Chmielewska, M.J. Hochmair, S. Lu, E. Nadal, G. Ostoros, E. Felip, A.I. Spira, C.M. Lane, J. He, R. Chao, P.A. Jänne
Journal: Annals of Oncology (2023)
LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD
Authors: A. Zaanan, O. Bouche, C. de la Fouchardiere, E. Samalin-Scalzi, K. Le Malicot, S. Pernot, P. Artru, V. Ly Lebrun, K. Aldabbagh, F. Khemissa Akouz, H. Castanie, M. Laly, D. Botsen, M. Muller, G. Roth, T. Lecomte, J.M. Phelip, C. Lepage, C. Louvet
Journal: Annals of Oncology (2023)
LBA62 Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study
Authors: A.R.R. Filippi, M.R. García-Campelo, J-B. Paoli, D. Kowalski, C. Bennati, P. Borghetti, D.L. Cortinovis, A. Delmonte, C. Genova, S. Van Hulst, R. Mroz, S. Nawrocki, I. Toledano, G. Tonini, I. Diaz Perez, N.E. Georgoulia, K. Foroutanpour, R. Dziadziuszko
Journal: Annals of Oncology (2023)
LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
Authors: A. Passaro, B.C. Cho, Y. Wang, B. Melosky, R. Califano, S-H. Lee, N. Girard, K.L. Reckamp, T. Takahashi, E. Felip, R.D. Gentzler, S. Popat, W. Nassib William Junior, T. Sun, S. Shah, B. Diorio, R.E. Knoblauch, J.M. Bauml, M.R. García-Campelo, J. Wang
Journal: Annals of Oncology (2023)
LBA99 First survival data from the NIPU trial: A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma
Authors: A. Helland, V.D. Haakensen, A.K. Ojlert, S.M.H. Thunold, A.K. Nowak, W.L. Chin, O. Grundberg, S.J. Farooqi, M. Lund-Iversen, W.M. Szejniuk, S.M. Cedres Perez, J.B. Sørensen, M.M. Bjaanaes
Journal: Annals of Oncology (2023)
LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Authors: D. Planchard, P.A. Jänne, Y. Cheng, C.K. Lee, K. Laktionov, T-Y. Yang, Y. Yu, T. Kato, L. Jiang, B. Chewaskulyong, S. Lucien Geater, J-M. Maurel, C. Rojas, L. Havel, F.A. Shepherd, K. Tanaka, D. Ghiorghiu, E. Armenteros Monterroso, X. Huang, J.C-H. Yang
Journal: Annals of Oncology (2023)
LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Authors: R-H. Xu, D-Y. Oh, K. Kato, T. Arkenau, J. Tabernero, M. Cruz-Correa, A. Zimina, Y. Bai, J. Shi, K-W. Lee, H. Hirano, D.R. Spigel, L.S. Wyrwicz, R.A. Pazo Cid, L. Li, Y. Xu, M.B. McHenry, S. Yang, M. Moehler
Journal: Annals of Oncology (2023)
LBA55 An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer
Authors: J.R.M. Black, A.M. Frankell, S. Veeriah, M. Colopi, M. Hill, C.W. Abbott, S.M. Boyle, B. Li, R. Chen, M. Al Bakir, C. Martinez Ruiz, A. Huebner, M. Jamal-Hanjani, N. McGranahan, C. Swanton
Journal: Annals of Oncology (2023)
LBA79 GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Authors: X. Zhang, J. Wang, G. Wang, Y. Zhang, Q. Fan, L. Chuangxin, C. Hu, M.L. Sun, Y. Wan, S. Sun, J. Wang, L. Zhang, Y. Shu, J. Luo, D. Zhu, H. Wang, Y. Xu, Q. Shi, J.J. Yang, L. Shen
Journal: Annals of Oncology (2023)
LBA93 EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)
Authors: Y. Cheng, Y. Liu, W. Zhang, L. Wu, C. Zhou, D. Wang, B. Xia, M. Bi, X. Fu, C. Li, G. Chen, D. Lv, Y. Zhao, J. Huang, M. Li, T. Yi, X. Huang, R. Yang, Z. Chen, Y. Wang
Journal: Annals of Oncology (2023)
LBA76 The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)
Authors: S. Kadowaki, D. Sakai, R. Kawabata, H. Hara, H. Yasui, M. Takahashi, M. Hirao, H. Imai, K. Minashi, T. Kawakami, H. Satake, J. Matsuyama, Y. Sakamoto, K. Sawada, M. Kataoka, H. Kawakami, T. Shimokawa, N. Boku, T. Satoh
Journal: Annals of Oncology (2023)
LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047
Authors: E.J. Lipson, S. Dolfi, H. Tang, H. Gogas, H.A. Tawbi, F.S. Hodi, P.A. Ascierto, E.C. Gutierrez, D. Schadendorf, F.A. Medina Soto, P. Rutkowski, E. Murillo Ramirez, M. Maio, Y. Xu, K. Desai, A. Yu, K. Demers, K. Miller-Moslin, G.V. Long, C. Garnett-Benson
Journal: Annals of Oncology (2023)
LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial
Authors: M. Reck, D. Gale, D. Harpole, J.M. Taube, T. Mitsudomi, M.J. Hochmair, T. Winder, Z. Zhu, Z. Lai, R. Stewart, D.R. Hodgson, G.J. Doherty, J.V. Heymach
Journal: Annals of Oncology (2023)
LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
Authors: H. Borghaei, M.L. Johnson, E.B. Garon, K. He, D. Planchard, M. Reck, S. Popat, R.S. Herbst, T.A. Leal, D. Dumoulin, F. de Marinis, C.H. Reynolds, W.S.M.E. Theelen, I. Percent, V. Gutierrez Calderon, A-C. Madroszyk Flandin, R.L. Shazer, X. Yan, R. Harrigan, S. Peters
Journal: Annals of Oncology (2023)
LBA81 Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Authors: F. Lordick, M.A. Shah, K. Shitara, J.A. Ajani, Y-J. Bang, P.C. Enzinger, D.H. Ilson, E. Van Cutsem, J. Gallego Plazas, J. Huang, L. Shen, S.C. Oh, P. Sunpaweravong, H.H.F. Soo, H.M. Türk, J.W. Park, D. Moran, P. Bhattacharya, Y.J. Cao, R-H. Xu
Journal: Annals of Oncology (2023)
LBA86 Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial
Authors: H. Grönberg, J. Lindberg, B. De Laere, A. Crippa, A. Discacciati, C.T. Karlsson, A. Ullén, E. Jänes, A. Mortezavi, P. Ost, G. Enblad, J. Oldenburg, J. Sandzén, L. Pettersson, M.N. Vigmostad, M.E. Hjälm-Eriksson, M. Olsson, P. Schatteman, C. Ghysel, M. Eklund
Journal: Annals of Oncology (2023)
LBA78 Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial
Authors: X. Zhang, Z. Li, H. Liang, Y. Xue, Y. Wang, Z. Zhou, J. Yu, L. Chen, Y. Du, G. Li, G. Xiao, D. Wu, Y. Zhou, C. Dang, Y. He, Z. Zhang, Y. Sun, Y. Li, L. Shen, J. Ji
Journal: Annals of Oncology (2023)
LBA91 TOMAS2: A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced, metastatic, or unresectable soft tissue sarcomas (STS) after failure of standard treatments
Authors: L. D'Ambrosio, A. Merlini, A. Brunello, V. Ferraresi, A. Paioli, B. Vincenzi, M.A. Pantaleo, T.M. De Pas, L. Gurrieri, R. Sanfilippo, A. Buonadonna, G.G. Baldi, G. Badalamenti, C. Marchiò, Y. Pignochino, G. Manessi, S. Aliberti, A.P. Dei Tos, S. Stacchiotti, G. Grignani
Journal: Annals of Oncology (2023)
LBA101 BRCA-DIRECT: A randomised UK study evaluating a digital pathway for germline genetic testing and non-inferiority of digitally-delivered information in women with breast cancer
Authors: B. Torr, S. Choi, S. Allen, M. Hamill, G. Kavanaugh, S. MacMahon, E. Poyastro-Pearson, L. Yuan, M. Valganon-Petrizan, A. George, V.A. Jenkins, L. Fallowfield, R. Manchanda, A. Gandhi, G. Evans, Z. Kemp, M. Hubank, C. Turnbull
Journal: Annals of Oncology (2023)
LBA97 Olanzapine for the prevention of chemotherapy induced nausea vomiting in patients receiving moderately emetogenic chemotherapeutic (MEC) regimens: Results of a prospective triple blinded phase III multicentric study (OMEC)
Authors: V.S. Ostwal, S. Mandavkar, M. Parulekar, A. Ramaswamy, P.G. Bhargava, S. Srinivas, D. Chaugule, D. Naughane, A. Kapoor, A. Gupta, B. Sansar, A. Sharma, R.K. Rai, P. Gupta, B. Mishra, V.K. Muddu, I.N. Olver
Journal: Annals of Oncology (2023)
LBA94 Effects of short-term fasting on quality of life as an add-on option during chemotherapy
Authors: D.A. Koppold, C. Kessler, M. Wischnewsky, I.M. Alvarado-Rupflin, C. Kempter, M. Paul, B. Brueckner, D. Fischer, N. Steckhan, M. Jeitler, E. Hanslian, B. Kunz, A. Michalsen
Journal: Annals of Oncology (2023)
LBA82 Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Authors: J.A. Ajani, F. Lordick, Y-J. Bang, P.C. Enzinger, D.H. Ilson, M.A. Shah, E. Van Cutsem, R-H. Xu, G. Aprile, J. Xu, R.A. Pazo Cid, Y-K. Kang, J. Yang, D. Moran, P. Bhattacharya, M. Matsangou, A. Arozullah, J.W. Park, K. Shitara
Journal: Annals of Oncology (2023)
LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Authors: Y.Y. Janjigian, S-E. Al-Batran, Z.A. Wainberg, E. Van Cutsem, D. Molena, K. Muro, W.J. Hyung, L.S. Wyrwicz, D-Y. Oh, T. Omori, M. Moehler, M. Garrido, S. Cunha Sousa Oliveira, M. Liberman, V. Castro Oliden, M. Bilici, J.F. Kurland, I. Xynos, H. Mann, J. Tabernero
Journal: Annals of Oncology (2023)
LBA60 Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer
Authors: Z-R. Zhao, S. Liu, T. Zhou, G. Chen, Z-H. Ye, Z-C. Li, J-D. Wu, Y. Yang, M. Xi, Y-B. Lin, H. Yang
Journal: Annals of Oncology (2023)
LBA89 Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
Authors: R.L. Jones, R. Sanfilippo, S.M. Schuetze, A. Sebio, R.M. Alvarez, N. Bui, A.J. Wagner, S.P. Chawla, T.W-W. Chen, D. Pink, A. Le Cesne, A. Italiano, B. Vincenzi, I.Z. Kiladze, S. Patel, R. Bryce, F. Xu, R.C. Doebele, G. Schwartz, M. Gounder
Journal: Annals of Oncology (2023)
LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
Authors: M-J. Ahn, A. Lisberg, L. Paz-Ares, R. Cornelissen, N. Girard, E. Pons-Tostivint, D. Vicente Baz, S. Sugawara, M. Cobo Dols, M. Pérol, C. Mascaux, E. Poddubskaya, S. Kitazono, H. Hayashi, J. Sands, R. Hall, Y. Zhang, H. Zebger-Gong, D. Uema, I. Okamoto
Journal: Annals of Oncology (2023)
LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
Authors: J.D. Spicer, S. Gao, M. Liberman, T. Kato, M. Tsuboi, S-H. Lee, K-N. Chen, C. Dooms, M. Majem, E. Eigendorff, G. Martinengo, O. Bylicki, M.C. Garassino, D. Rodriguez Abreu, J. Chaft, S. Novello, J. Yang, S.M. Keller, A. Samkari, H. Wakelee
Journal: Annals of Oncology (2023)
LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial
Authors: S. Piperno-Neumann, J.C. Hassel, P. Rutkowski, J-F. Baurain, M. Schlaak, M.O. Butler, R.J. Sullivan, R. Dummer, J.M. Kirkwood, M. Orloff, J.J. Sacco, S. Ochsenreither, A.M. Joshua, L. Gastaud, B. Curti, R.D. Carvajal, O. Hamid, L. Collins, C. Holland, P. Nathan
Journal: Annals of Oncology (2023)
LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
Authors: L. Albiges, B.I. Rini, K. Peltola, G.A. De Velasco Oria, M. Burotto, C. Suarez Rodriguez, P. Ghatalia, R. Iacovelli, E.T. Lam, E. Verzoni, M. Gumus, W.M. Stadler, C.K. Kollmannsberger, B. Melichar, B. Venugopal, A. Wang, R. Perini, D. Vickery, T.B. Powles, T.K. Choueiri
Journal: Annals of Oncology (2023)
LBA64 Overall survival from a phase II randomised double-blind trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC
Authors: S. Peters, A.L.O. Ortega Granados, F. de Marinis, G. Lo Russo, M. Schenker, E. Arriola, J.M. Puig, D.H. Lee, M. Reck, Z. Szijgyarto, E. Buss, N. Stjepanovic, S.M. Lim
Journal: Annals of Oncology (2023)
LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial
Authors: D. Yue, W. Wang, H. Liu, Q. Chen, C. Chen, J. Zhang, F. Bai, C. Wang
Journal: Annals of Oncology (2023)
LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression
Authors: M. Provencio Pulla, P.M. Forde, J.D. Spicer, C. Wang, S. Lu, T. Mitsudomi, M.M. Awad, E. Felip, S. Broderick, S.J. Swanson, J.R. Brahmer, K.M. Kerr, G. Saylors, F. Tanaka, K-N. Chen, M.P. Tran, J.L. Cai, J. Mahmood, S. Meadows-Shropshire, N. Girard
Journal: Annals of Oncology (2023)
LBA72 DARWIN II: Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC
Authors: C. Hiley, S. Saghafinia, T. Ahmad, M.G. Krebs, D.A. Fennell, S. Baijal, N. Steele, G. Price, C. Lombardelli, W.K. Liu, C. Castignani, K. Enfield, B. Chain, S. Quezada, G. Kassiotis, K.R. Litchfield, N. McGranahan, A. Hackshaw, M. Jamal-Hanjani, C. Swanton
Journal: Annals of Oncology (2023)
LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)
Authors: T.K. Choueiri, T. Bauer, J.R. Merchan, D.F. McDermott, R. Figlin, E. Arrowsmith, M.D. Michaelson, E. Heath, A.A. D'Souza, S. Zhao, L. Mhamdi, R. Perini, D. Vickery, S. Tykodi
Journal: Annals of Oncology (2023)
LBA3 Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer
Authors: J. Hadoux, R. Elisei, M.S. Brose, A. Hoff, B. Robinson, M. Gao, B. Jarzab, P. Isaev, K. Kopeckova, J. Wadsley, D. Führer, B. Keam, E.J. Sherman, M. Tahara, M.I. Hu, Y. Lin, P. Maeda, L.J. Wirth, J. Capdevila Castillon
Journal: Annals of Oncology (2023)
LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial
Authors: M.S. van der Heijden, G.P. Sonpavde, T.B. Powles, A. Necchi, M. Burotto, M. Schenker, J.P. Sade, A. Bamias, P. Beuzeboc, J. Bedke, J. Oldenburg, Y. Urun, D. Ye, Z. He, B. Perez Valderrama, Y. Tomita, J. Filian, D. Purcea, F. Nasroulah, M.D. Galsky
Journal: Annals of Oncology (2023)
LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)
Authors: L. Emmett, S. Subramaniam, M. Crumbaker, A.M. Joshua, A.J. Weickhardt, S.T. Lee, S. Ng, R.J. Francis, J.C.H. Goh, D.A. Pattison, H. Tan, I.D. Kirkwood, S.K. Sandhu, A. Nguyen, C. Gedye, N. Rutherford, M. Hofman, A. Martin, M.R. Stockler, I.D. Davis
Journal: Annals of Oncology (2023)
LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
Authors: B.C. Cho, E. Felip, A.I. Spira, N. Girard, J-S. Lee, S-H. Lee, Y.V. Ostapenko, P. Danchaivijitr, B. Liu, A. Alip, E.P. Korbenfeld, J. Dias, T. Sun, M. Martinez, J.M. Bauml, M. Shreeve, S. Sethi, R.E. Knoblauch, H. Hayashi, S. Lu
Journal: Annals of Oncology (2023)
LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)
Authors: S. Miura, H. Tanaka, T. Misumi, H. Yoshioka, T. Kurata, T. Tokito, T. Fukuhara, Y. Sato, Y. Shiraishi, S. kusuhara, S. Teraoka, T. Kato, H. Horinouchi, Y. Takiguchi, Y. Goto, K. Tanaka, M. Kanazu, S. Ikeda, E. Ichihara, H. Okamoto
Journal: Annals of Oncology (2023)
LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
Authors: X. Le, J. Patel, E. Shum, R.E. Sanborn, C.S. Baik, C.A. Shu, C. Kim, M.D. Fidler, R. Hall, N. Hanna, N. Mohindra, J.K. Sabari, S. Heeke, M. Hernandez, J.E. Gray, J.V. Heymach, A. Saltos
Journal: Annals of Oncology (2023)
LBA10 Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study
Authors: F. Pietrantonio, L. Salvatore, T. Esaki, D.P. Modest, D. Paez, J. Taieb, M.V. Karamouzis, E. Ruiz, T.W. Kim, Y. Kuboki, F.A. Meriggi, D. Cunningham, K-H. Yeh, E. Chan, J. Chao, N. Strydom, Y. Saportas, Q. Tran, C. Cremolini, M. Fakih
Journal: Annals of Oncology (2023)
LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
Authors: C. Zhou, W. Li, Z. Song, Y. Zhang, Y. Zhang, D. Huang, Z. Yang, M. Zhou, R. Mao, C. Huang, X. Li, J. Wang
Journal: Annals of Oncology (2023)